Modified FGF-1 Polypeptide for Dry Eye Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for dry eye are not consistently effective, and there is a need for new therapeutic modalities to address this prevalent ocular disorder.
Innovation Solution
A method of treating dry eye by administering a pharmaceutical composition containing a therapeutically effective amount of a modified FGF-1 polypeptide, specifically with mutations Cys16Ser, Ala66Cys, and Cys117Val, which is designed for ocular delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for dry eye are used, then treatment is provided, but they are not consistently effective
Solution Approach 1:
The patent modifies the FGF-1 polypeptide by changing specific amino acid parameters (Cys16Ser, Ala66Cys, Cys117Val mutations) to create a thermostable variant. This parameter change in the protein structure improves reliability of treatment effectiveness while the targeted approach addresses consistency across different patients by providing a standardized effective dosage
2Reliability
If modified FGF-1 polypeptide is administered, then tear film stability and ocular surface health are improved, but the complexity of the pharmaceutical composition increases
Solution Approach 1:
The patent creates a composite pharmaceutical composition that combines the thermostable FGF-1 polypeptide with specific excipients (humectants like glycerin or hyaluronic acid, surfactants like polysorbate 80, and buffers). This composite approach maintains reliability of ocular surface health improvement while managing composition complexity through standardized formulation components
Data Source
AI summary
Described herein are methods of treating a disease, disorder or a condition associated with dry eye caused by a multifactorial disease of ocular surface, comprising administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of a modified FGF-1 polypeptide.